Hassani, Yasmine <br/><br/>
[Monitoring and evaluation tools for irinotecan and bevacizumab in glioblastoma: from prescription to patient's information].  [electronic resource] 

 -  Bulletin du cancer  May 2012 
 - 513-20 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1769-6917 
<br/><br/><label>Standard No.: </label>10.1684/bdc.2012.1573  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bevacizumab<br/>Brain Neoplasms--drug therapy<br/>Camptothecin--administration & dosage<br/>Contraindications<br/>Drug Monitoring--methods<br/>Family<br/>France<br/>General Practice<br/>Glioblastoma--drug therapy<br/>Humans<br/>Irinotecan<br/>Medical Oncology--methods<br/>Off-Label Use<br/>Pamphlets<br/>Patient Education as Topic--methods<br/>Pharmaceutical Services<br/>Pharmacovigilance<br/>Prescription Drugs--economics